Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

(2015)   Oncotarget

Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides

(2010) Jerome C. Bressi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound  -phenylethyl isothiocyanate

(2010) Y. Hu et al.   BLOOD

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

(2010) Bin Zhang et al.   CANCER CELL

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

(2010) Dana Rathkopf et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

(2010) Peter M. Wilson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours

(2010) Helen J. Mackay et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

(2010) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

(2010) Anne Hansen Ree et al.   LANCET ONCOLOGY

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

(2010) V. Novotny-Diermayr et al.   MOLECULAR CANCER THERAPEUTICS

Chemical phylogenetics of histone deacetylases

(2010) James E Bradner et al.   Nature Chemical Biology

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

(2010) O. Khan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

(2009) Monica Galli et al.   ANNALS OF HEMATOLOGY

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

(2009) L. R. Molife et al.   ANNALS OF ONCOLOGY

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts

(2009) Anne Monks et al.   ANTI-CANCER DRUGS

Identification of novel regulators of hematopoietic stem cell development through refinement of stem cell localization and expression profiling

(2009) M. I. Mascarenhas et al.   BLOOD

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

(2009) T. E. Fandy et al.   BLOOD

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines

(2009) Melissa J LaBonte et al.   BMC Medical Genomics

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

(2009) P N Munster et al.   BRITISH JOURNAL OF CANCER

A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

(2009) A Rocca et al.   BRITISH JOURNAL OF CANCER

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

(2009) Kristie A. Blum et al.   BRITISH JOURNAL OF HAEMATOLOGY

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)

(2009) Deborah Bradley et al.   CANCER

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

(2009) Susan Fotheringham et al.   CANCER CELL

Biomarkers for predicting clinical responses to HDAC inhibitors

(2009) Lindsay Stimson et al.   CANCER LETTERS

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

HDACi – Targets beyond chromatin

(2009) Marc Buchwald et al.   CANCER LETTERS

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors

(2009) Yutaka Fujiwara et al.   CANCER SCIENCE

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma

(2009) Takashi Watanabe et al.   CANCER SCIENCE

Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes

(2009) Zhibin Wang et al.   CELL

A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors

(2009) J. Lin et al.   CLINICAL CANCER RESEARCH

Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

(2009) M. T. Voso et al.   CLINICAL CANCER RESEARCH

A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer

(2009) M. G. Fakih et al.   CLINICAL CANCER RESEARCH

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

(2009) A. I. Daud et al.   CLINICAL CANCER RESEARCH

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

(2009) P. Munster et al.   CLINICAL CANCER RESEARCH

Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug Discovery

(2009) A. Ganesan et al.   CURRENT CANCER DRUG TARGETS

Histone Deacetylase Inhibitors

(2009) Xujun Ma et al.   DRUGS

A phase 2 study of vorinostat in acute myeloid leukemia

(2009) E. W. Schaefer et al.   HAEMATOLOGICA

In Reply

(2009) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma

(2009) Luis H. Camacho et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

(2009) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2009) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

(2009) Axel Hauschild et al.   MELANOMA RESEARCH

Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease

(2009) Mark Kilgore et al.   NEUROPSYCHOPHARMACOLOGY

Histone deacetylase inhibitor apicidin-mediated drug resistance: Involvement of P-glycoprotein

(2008) Yong Kee Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS

Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

(2008) V. R. Fantin et al.   CANCER RESEARCH

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

(2008) C. Bonfils et al.   CLINICAL CANCER RESEARCH

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

(2008) Robert P. Whitehead et al.   INVESTIGATIONAL NEW DRUGS

Destabilization of ERBB2 Transcripts by Targeting 3' Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6

(2008) G. K. Scott et al.   MOLECULAR CANCER RESEARCH

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

(2008) M. Fournel et al.   MOLECULAR CANCER THERAPEUTICS

Chromatin-remodelling mechanisms in cancer

(2008) Laura Lafon-Hughes et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

Therapeutic application of histone deacetylase inhibitors for central nervous system disorders

(2008) Aleksey G. Kazantsev et al.   NATURE REVIEWS DRUG DISCOVERY

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

(2008) Michael Haberland et al.   NATURE REVIEWS GENETICS

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice

(2008) E. A. Thomas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA